{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:28Z","timestamp":1791546628088,"version":"4.3.4"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian Research Council\u2019s Discovery Projects","award":["DP120102778"],"award-info":[{"award-number":["DP120102778"]}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["APP1065046"],"award-info":[{"award-number":["APP1065046"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.addr.2014.10.022","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T21:30:03Z","timestamp":1414186203000},"page":"83-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":230,"special_numbering":"C","title":["Inhaled formulations and pulmonary drug delivery systems for respiratory infections"],"prefix":"10.1016","volume":"85","author":[{"given":"Qi (Tony)","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Shui Yee","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaigarajan","family":"Parumasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Hui","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2014.10.022_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1517\/17425247.2012.660480","article-title":"Inhaled colistin for lower respiratory tract infections","volume":"9","author":"Antoniu","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0010","author":"WHO","year":"2004"},{"key":"10.1016\/j.addr.2014.10.022_bb0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/17425240903110710","article-title":"Delivery of antibiotics to the respiratory tract: an update","volume":"6","author":"Traini","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0020","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/AAC.01127-13","article-title":"Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections","volume":"57","author":"Yapa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0025","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.022_bb0035","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.03.006","article-title":"Emerging inhalation aerosol devices and strategies: where are we headed?","volume":"75","author":"Zhou","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0045","article-title":"Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead","author":"Velkov","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0050","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/ppa.13.47","article-title":"Inhaled antibiotics to treat lung infection","volume":"2","author":"Cipolla","year":"2013","journal-title":"Pharm. Patent Anal."},{"key":"10.1016\/j.addr.2014.10.022_bb0055","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2165\/11318500-000000000-00000","article-title":"Emerging treatments in cystic fibrosis","volume":"69","author":"Jones","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2014.10.022_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-9-32","article-title":"Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"9","author":"Hoiby","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2013.11.007","article-title":"Delivery of inhalation drugs to children for asthma and other respiratory diseases","volume":"73","author":"Kwok","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0070","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1378\/chest.125.2.502","article-title":"Comparison of lung deposition in two types of nebulization \u2014 intrapulmonary percussive ventilation vs jet nebulization","volume":"125","author":"Reychler","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.022_bb0075","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1039\/b903575c","article-title":"Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization","volume":"9","author":"Qi","year":"2009","journal-title":"Lab Chip"},{"key":"10.1016\/j.addr.2014.10.022_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1465-9921-15-60","article-title":"Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization","volume":"15","author":"Rajapaksa","year":"2014","journal-title":"Respir. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2014.10.022_bb0085","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1089\/jamp.2009.0786","article-title":"Mode of breathing-tidal or slow and deep-through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of (99m) Tc-DTPA","volume":"23","author":"Nikander","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4155\/tde.10.54","article-title":"Personalizing aerosol medicine: development of delivery systems tailored to the individual","volume":"1","author":"Cipolla","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.022_bb0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.022_bb0105","unstructured":"M.J. Harrison, M. McCarthy, C. Fleming, C. Hickey, C. Shortt, J.A. Eustace, D.M. Murphy, B.J. Plant, Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF), Journal of Cystic Fibrosis."},{"key":"10.1016\/j.addr.2014.10.022_bb0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2214.2006.00669.x","article-title":"Microbial contamination of nebulizers in the home treatment of cystic fibrosis","volume":"33","author":"Blau","year":"2007","journal-title":"Child Care Health Dev."},{"key":"10.1016\/j.addr.2014.10.022_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1081\/JAS-200054625","article-title":"Bacterial contamination of spacer devices used by asthmatic children","volume":"42","author":"Cohen","year":"2005","journal-title":"J. Asthma"},{"key":"10.1016\/j.addr.2014.10.022_bb0120","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/jam.2004.17.354","article-title":"Bacterial contamination of inhalation chambers: results of a pilot study","volume":"17","author":"De Vries","year":"2004","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.addr.2011.07.002","article-title":"Drug\u2013lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces","volume":"64","author":"Zhou","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.10.022_bb0130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1089\/jamp.2010.0838","article-title":"Pulmonary formulations: what remains to be done?","volume":"23","author":"Weers","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejpb.2012.10.015","article-title":"The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules","volume":"83","author":"Sou","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijpharm.2011.09.018","article-title":"Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach","volume":"421","author":"Sou","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11095-013-1174-5","article-title":"Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery","volume":"31","author":"Hoe","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.powtec.2008.11.005","article-title":"Direct evidence on reduced adhesion of Salbutamol sulphate particles due to L-leucine coating","volume":"192","author":"Paajanen","year":"2009","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2009.10.036","article-title":"Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders","volume":"385","author":"Raula","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a Phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.addr.2014.10.022_bb0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4155\/tde.14.3","article-title":"The PulmoSphere\u2122 platform for pulmonary drug delivery","volume":"5","author":"Weers","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0175","series-title":"Respir. Drug Deliv.","first-page":"701","article-title":"Aerosol performance of tobramycin inhalation powder","author":"Haynes","year":"2010"},{"key":"10.1016\/j.addr.2014.10.022_bb0180","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/jam.2006.19.456","article-title":"Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older","volume":"19","author":"Tiddens","year":"2006","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0185","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11095-007-9381-6","article-title":"Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin","volume":"25","author":"Fiegel","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0190","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tube.2003.08.016","article-title":"Direct lung delivery of para-aminosalicylic acid by aerosol particles","volume":"83","author":"Tsapis","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/j.addr.2014.10.022_bb0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.2042-7158.2012.01465.x","article-title":"Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state","volume":"64","author":"Gad","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2014.10.022_bb0205","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejpb.2011.02.004","article-title":"A new respirable form of rifampicin","volume":"78","author":"Son","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0210","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jps.23911","article-title":"A novel inhalable form of rifapentine","volume":"103","author":"Chan","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2010.04.032","article-title":"Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach","volume":"394","author":"Zhou","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1208\/s12249-012-9895-z","article-title":"Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers","volume":"14","author":"Zhou","year":"2013","journal-title":"AAPS Pharmscitech"},{"key":"10.1016\/j.addr.2014.10.022_bb0225","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1002\/jps.22547","article-title":"Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach","volume":"100","author":"Zhou","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0230","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejps.2010.04.012","article-title":"Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders","volume":"40","author":"Zhou","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0235","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11095-009-9825-2","article-title":"Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency","volume":"26","author":"Parlati","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijpharm.2014.05.055","article-title":"Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction","volume":"471","author":"Belotti","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0245","article-title":"Inhaled antimicrobial therapy \u2014 barriers to effective treatment","author":"Weers","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-5173(02)00038-8","article-title":"A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy","volume":"237","author":"Columbano","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0255","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1002\/jps.22484","article-title":"Characterization and quantification of amorphous material in milled and spray-dried salbutamol sulfate: a comparison of thermal, spectroscopic, and water vapor sorption approaches","volume":"100","author":"Grisedale","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.addr.2011.11.001","article-title":"Isothermal microcalorimetry for quantifying amorphous content in processed pharmaceuticals","volume":"64","author":"Gaisford","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0265","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejps.2010.03.020","article-title":"Co-spray-dried mannitol\u2013ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease","volume":"40","author":"Adi","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0270","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/jps.23685","article-title":"Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation","volume":"102","author":"Zhou","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0275","series-title":"Respiratory Drug Delivery Europe 2011","first-page":"367","article-title":"Investigating the particle engineering of colistin for pulmonary delivery","author":"Morton","year":"2011"},{"key":"10.1016\/j.addr.2014.10.022_bb0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-013-9537-8","article-title":"Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection","volume":"16","author":"Zhou","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2014.10.022_bb0285","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425247.4.2.95","article-title":"Liposome-based drug delivery to alveolar macrophages","volume":"4","author":"Vyas","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0290","article-title":"Targeted liposomal drug delivery to monocytes and macrophages","volume":"727241","author":"Kelly","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0295","series-title":"2014 American Thoracic Society Conference","article-title":"Liposomal ciprofloxacin preparation is active against Mycobacterium avium subsp hominissuis and Mycobacterium abscessus in macrophages and in biofilm","author":"Blanchard","year":"2014"},{"key":"10.1016\/j.addr.2014.10.022_bb0300","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/03639040903099744","article-title":"Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages","volume":"36","author":"Chono","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2007.12.011","article-title":"Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections","volume":"127","author":"Chono","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb0310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.addr.2014.05.001","article-title":"Lipid-based carriers for pulmonary products: preclinical development and case studies in humans","volume":"75","author":"Cipolla","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0315","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.022_bb0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","article-title":"Characterization of nebulized liposomal amikacin (Arikace (TM)) as a function of droplet size","volume":"21","author":"Li","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0325","first-page":"407","article-title":"Triggered release of ciprofloxacin from nanostructured agglomerated vesicles","volume":"2","author":"Bhavane","year":"2007","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.10.022_bb0330","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/jps.23969","article-title":"Modifying the release properties of liposomes toward personalized medicine","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0335","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.022_bb0340","series-title":"Respiratory, Drug Delivery","first-page":"73","article-title":"Inhaled liposomal ciprofloxacin: once a day management of respiratory infections","author":"Bruinenberg","year":"2010"},{"key":"10.1016\/j.addr.2014.10.022_bb0345","series-title":"Respiratory Drug Delivery Orlando, FL","article-title":"Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance","author":"Cipolla","year":"2010"},{"key":"10.1016\/j.addr.2014.10.022_bb0350","series-title":"Respiratory Drug Delivery Europe 2013, Berlin, Germany","article-title":"Liposomal ciprofloxacin for inhalation retains integrity following nebulization","author":"Cipolla","year":"2013"},{"key":"10.1016\/j.addr.2014.10.022_bb0355","first-page":"1","article-title":"Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties","author":"Cipolla","year":"2014","journal-title":"AAPS Pharmscitech"},{"key":"10.1016\/j.addr.2014.10.022_bb0360","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijpharm.2012.06.064","article-title":"Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients","volume":"436","author":"Elhissi","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0365","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0168-3659(02)00264-X","article-title":"A facile method of delivery of liposomes by nebulization","volume":"84","author":"Desai","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb0370","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jps.10021","article-title":"A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling","volume":"91","author":"Desai","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0375","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejps.2003.09.008","article-title":"Delivery of liposomes in dry powder form: aerodynamic dispersion properties","volume":"20","author":"Desai","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0380","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2005.09.010","article-title":"Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery","volume":"305","author":"Sweeney","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0385","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/17425247.2013.822860","article-title":"Liposomal antibiotics for the treatment of infectious diseases","volume":"10","author":"Alhariri","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0390","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/157018007784620040","article-title":"In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains","volume":"4","author":"Gubernator","year":"2007","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.addr.2014.10.022_bb0395","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2008.09.043","article-title":"The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell","volume":"367","author":"Drulis-Kawa","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0400","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1023\/A:1022664406840","article-title":"In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate","volume":"20","author":"Desai","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0405","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2217\/fmb.13.39","article-title":"Pharmacology of polymyxins: new insights into an \u2018old\u2019 class of antibiotics","volume":"8","author":"Velkov","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/j.addr.2014.10.022_bb0410","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/jps.23203","article-title":"Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation","volume":"101","author":"Wallace","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0415","first-page":"159","article-title":"Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo","volume":"63","author":"Wang","year":"2009","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb0420","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/jps.23508","article-title":"Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies","volume":"102","author":"Wallace","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0425","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1773-2247(05)50047-9","article-title":"Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers","volume":"15","author":"Elhissi","year":"2005","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb0430","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0168-3659(02)00238-9","article-title":"Preparation and evaluation of proliposomes containing salmon calcitonin","volume":"84","author":"Song","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb0435","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms12074414","article-title":"Isoniazid proliposome powders for inhalation\u2013preparation, characterization and cell culture studies","volume":"12","author":"Rojanarat","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0440","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pupt.2013.07.006","article-title":"Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach","volume":"27","author":"Patil-Gadhe","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.10.022_bb0445","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1208\/s12249-012-9822-3","article-title":"Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)","volume":"13","author":"Riley","year":"2012","journal-title":"AAPS Pharmscitech"},{"key":"10.1016\/j.addr.2014.10.022_bb0450","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jps.23795","article-title":"Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0455","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11095-012-0827-0","article-title":"Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia","volume":"29","author":"Ong","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0460","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal formulations for inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb0465","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1002\/jps.21653","article-title":"Preparation and evaluation of controlled release microparticles for respiratory protein therapy","volume":"98","author":"Salama","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0470","doi-asserted-by":"crossref","first-page":"e62115","DOI":"10.1371\/journal.pone.0062115","article-title":"Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles","volume":"8","author":"Roberts","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.10.022_bb0475","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2006.01.016","article-title":"Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung","volume":"215","author":"Dailey","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.addr.2014.10.022_bb0480","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0046-8177(88)80204-1","article-title":"Long term histopathologic follow-up of bronchial arteries after therapeutic embolization with polyvinyl alcohol (Ivalon) in patients with cystic fibrosis","volume":"19","author":"Tomashefski","year":"1988","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.addr.2014.10.022_bb0485","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/03639040903099769","article-title":"Controlled release antibiotics for dry powder lung delivery","volume":"36","author":"Adi","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0490","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s11095-010-0142-6","article-title":"Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile","volume":"27","author":"Cheow","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0495","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.colsurfa.2011.08.035","article-title":"The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics","volume":"389","author":"Cheow","year":"2011","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.addr.2014.10.022_bb0500","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","article-title":"Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers","volume":"157","author":"Ungaro","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb0505","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.2042-7158.2012.01531.x","article-title":"Preparation of sustained release rifampicin microparticles for inhalation","volume":"64","author":"Son","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2014.10.022_bb0510","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijpharm.2009.08.008","article-title":"Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization","volume":"382","author":"Doan","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0515","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.colsurfb.2008.08.010","article-title":"Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles","volume":"67","author":"Manca","year":"2008","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2014.10.022_bb0520","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2011.05.007","article-title":"Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery","volume":"414","author":"Doan","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0525","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ijpharm.2012.07.036","article-title":"Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting","volume":"436","author":"Diab","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijpharm.2006.11.061","article-title":"Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content","volume":"336","author":"Budhian","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0535","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.colsurfb.2008.05.011","article-title":"Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique","volume":"66","author":"Ito","year":"2008","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2014.10.022_bb0540","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.colsurfb.2012.02.030","article-title":"Preparation and characterization of rifampicin-PLGA microspheres\/sodium alginate in situ gel combination delivery system","volume":"95","author":"Hu","year":"2012","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2014.10.022_bb0545","series-title":"Study on Rifapentine-sodium Alginate Microspheres for Lung Targeting Drug Delivery","author":"Yang","year":"2011"},{"key":"10.1016\/j.addr.2014.10.022_bb0550","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/02652048.2011.599437","article-title":"Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid","volume":"28","author":"Pourshahab","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2014.10.022_bb0555","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.addr.2010.11.002","article-title":"Formation, characterization, and fate of inhaled drug nanoparticles","volume":"63","author":"Zhang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb0560","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijpharm.2011.12.045","article-title":"A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles","volume":"424","author":"Wang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0565","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.08.010","article-title":"Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former","volume":"420","author":"Yamasaki","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0570","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0575","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijpharm.2010.11.021","article-title":"Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants","volume":"404","author":"Cheow","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0580","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s11095-013-1120-6","article-title":"Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying","volume":"30","author":"D'Addio","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0585","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2012.01.048","article-title":"Constant size, variable density aerosol particles by ultrasonic spray freeze drying","volume":"427","author":"D'Addio","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0590","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/08982100903103904","article-title":"Development and optimization of solid lipid nanoparticles of amikacin by central composite design","volume":"20","author":"Varshosaz","year":"2010","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0595","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10837450.2010.529149","article-title":"Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design","volume":"17","author":"Varshosaz","year":"2012","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb0600","first-page":"35","article-title":"Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles","volume":"6","author":"Ghaffari","year":"2010","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.10.022_bb0605","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12247-010-9082-2","article-title":"Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols","volume":"5","author":"El-Gendy","year":"2010","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.addr.2014.10.022_bb0610","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2008.08.014","article-title":"Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery","volume":"365","author":"Pilcer","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0615","author":"Savara, Inc."},{"key":"10.1016\/j.addr.2014.10.022_bb0620","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/jps.23168","article-title":"Development of budesonide nanocluster dry powder aerosols: processing","volume":"101","author":"El-Gendy","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0625","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.2014.27","article-title":"Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product","volume":"95","author":"Backman","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.10.022_bb0630","author":"Savara, Inc."},{"key":"10.1016\/j.addr.2014.10.022_bb0635","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0640","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMp1101548","article-title":"Development of novel combination therapies","volume":"364","author":"Woodcock","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0645","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1002\/jps.21239","article-title":"Cospray dried antibiotics for dry powder lung delivery","volume":"97","author":"Adi","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0650","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/ng1755","article-title":"Functional classification of drugs by properties of their pairwise interactions","volume":"38","author":"Yeh","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2014.10.022_bb0655","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/dkp282","article-title":"Antibacterial activities of a fosfomycin\/tobramycin combination: a novel inhaled antibiotic for bronchiectasis","volume":"64","author":"MacLeod","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0660","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/AAC.05958-11","article-title":"Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa","volume":"56","author":"MacLeod","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0665","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijantimicag.2009.04.010","article-title":"Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa","volume":"34","author":"Tre-Hardy","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.addr.2014.10.022_bb0670","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1128\/AAC.00372-10","article-title":"Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model","volume":"54","author":"Tre-Hardy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0675","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/656788","article-title":"Colistin\u2013tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa","volume":"202","author":"Herrmann","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.10.022_bb0680","first-page":"338-338","article-title":"Fosfomycin\/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa","author":"McColley","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.022_bb0685","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpb.2012.09.002","article-title":"Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation","volume":"83","author":"Lee","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0690","first-page":"192","article-title":"Ineffectiveness of lysozyme therapy in experimental syphilis in the rabbit","volume":"39","author":"Cannefax","year":"1963","journal-title":"Br. J. Venereal Dis."},{"key":"10.1016\/j.addr.2014.10.022_bb0695","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1208\/s12248-008-9033-8","article-title":"Microparticles for inhalational delivery of antipseudomonal antibiotics","volume":"10","author":"Tsifansky","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2014.10.022_bb0700","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2013.04.069","article-title":"Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis","volume":"451","author":"Pilcer","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0705","first-page":"1239","article-title":"Formulation and evaluation of dry powders containing anti tuberculosis drugs for pulmonary delivery","volume":"3","author":"Gowda","year":"2013","journal-title":"Indo Am. J. Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0710","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejps.2007.06.006","article-title":"Inhalable microparticles containing large payload of anti-tuberculosis drugs","volume":"32","author":"Muttil","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0715","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijpharm.2013.01.038","article-title":"In vivo\/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid","volume":"444","author":"Booysen","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0720","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2012.08.007","article-title":"A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics","volume":"83","author":"Chan","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0725","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1023\/A:1012296604685","article-title":"Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis","volume":"18","author":"Sharma","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0730","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00006454-199111000-00007","article-title":"Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children","volume":"10","author":"Seifart","year":"1991","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.10.022_bb0735","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QCO.0b013e32830634d8","article-title":"The role of chelators in preventing biofilm formation and catheter-related bloodstream infections","volume":"21","author":"Raad","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.10.022_bb0740","first-page":"363","article-title":"Antibiotic-EDTA combination induced dispersal of Pseudomonas aeruginosa biofilm","volume":"6","author":"Shaikh","year":"2012","journal-title":"J. Pure Appl. Microbiol."},{"key":"10.1016\/j.addr.2014.10.022_bb0745","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/417552a","article-title":"A component of innate immunity prevents bacterial biofilm development","volume":"417","author":"Singh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.addr.2014.10.022_bb0750","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2014.10.022_bb0755","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.022_bb0760","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10069","article-title":"Metabolite-enabled eradication of bacterial persisters by aminoglycosides","volume":"473","author":"Allison","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2014.10.022_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084220","article-title":"Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms","volume":"8","author":"Barraud","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.10.022_bb0770","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1164\/rccm.201109-1666OC","article-title":"Long-term inhaled dry powder mannitol in cystic fibrosis an international randomized study","volume":"185","author":"Aitken","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0775","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1378\/chest.12-1763","article-title":"Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis","volume":"144","author":"Bilton","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.022_bb0780","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11095-009-9991-2","article-title":"Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis","volume":"27","author":"Yang","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0785","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jps.23874","article-title":"Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy","volume":"103","author":"Lee","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0790","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1128\/JB.00779-06","article-title":"Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa","volume":"188","author":"Barraud","year":"2006","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2014.10.022_bb0795","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1128\/JB.00975-09","article-title":"Nitric oxide signaling in pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic Di-GMP levels, and enhanced dispersal","volume":"191","author":"Barraud","year":"2009","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2014.10.022_bb0800","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1751-7915.2009.00098.x","article-title":"Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms","volume":"2","author":"Barraud","year":"2009","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.addr.2014.10.022_bb0805","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1126\/science.1188628","article-title":"D-amino acids trigger biofilm disassembly","volume":"328","author":"Kolodkin-Gal","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2014.10.022_bb0810","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1586\/eri.11.90","article-title":"Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens","volume":"9","author":"Burrowes","year":"2011","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.addr.2014.10.022_bb0815","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tim.2008.11.002","article-title":"Preventing biofilms of clinically relevant organisms using bacteriophage","volume":"17","author":"Donlan","year":"2009","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2014.10.022_bb0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1097(04)00041-2","article-title":"The interaction of phage and biofilms","volume":"232","author":"Sutherland","year":"2004","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.addr.2014.10.022_bb0825","doi-asserted-by":"crossref","first-page":"11197","DOI":"10.1073\/pnas.0704624104","article-title":"Dispersing biofilms with engineered enzymatic bacteriophage","volume":"104","author":"Lu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.10.022_bb0830","series-title":"Modified-release Drug Delivery Technology","first-page":"631","article-title":"Formulation challenges: protein powders for inhalation","author":"Chan","year":"2008"},{"key":"10.1016\/j.addr.2014.10.022_bb0835","series-title":"Respiratory Drug Delivery V","first-page":"167","article-title":"The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example","author":"Clark","year":"1996"},{"key":"10.1016\/j.addr.2014.10.022_bb0840","series-title":"Peptide and Protein Delivery","first-page":"23","article-title":"Pulmonary delivery of peptides and proteins","author":"Kwok","year":"2011"},{"key":"10.1016\/j.addr.2014.10.022_bb0845","series-title":"Inhalation Drug Delivery: Techniques and Products","first-page":"121","article-title":"Proteins, peptides, and controlled-release formulations for inhalation","author":"Kwok","year":"2012"},{"key":"10.1016\/j.addr.2014.10.022_bb0850","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1012035113276","article-title":"Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery","volume":"14","author":"Chan","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0855","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/js9504292","article-title":"Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase)","volume":"87","author":"Chan","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0860","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1023\/A:1011993620177","article-title":"A solid-state NMR study of protein hydration and stability","volume":"15","author":"Separovic","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0865","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/jps.10089","article-title":"A solid-state NMR study of protein mobility in lyophilized protein-sugar powders","volume":"91","author":"Lam","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0870","series-title":"Respiratory Drug Delivery IV","first-page":"47","article-title":"A case study in aerosol protein drug development: aqueous solution aerosols of rhDNase","author":"Gonda","year":"1994"},{"key":"10.1016\/j.addr.2014.10.022_bb0875","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1023\/A:1007551006782","article-title":"Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide","volume":"17","author":"Bustami","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0880","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/089426802760292717","article-title":"Aerosolization of protein solutions using thermal inkjet technology","volume":"15","author":"Goodall","year":"2002","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0885","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1002\/jps.21653","article-title":"Preparation and evaluation of controlled release microparticles for respiratory protein therapy","volume":"98","author":"Salama","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0890","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2010.10.012","article-title":"Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy","volume":"403","author":"Lee","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0895","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11095-010-0332-2","article-title":"Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery","volume":"28","author":"Kwok","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb0900","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1016\/j.vaccine.2013.07.022","article-title":"TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines","volume":"31","author":"Tyne","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2014.10.022_bb0905","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1002\/jps.22715","article-title":"Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections","volume":"100","author":"Matinkhoo","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0910","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2672.2010.04863.x","article-title":"In vitro lung delivery of bacteriophages KS4-M and \u03a6KZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis","volume":"110","author":"Golshahi","year":"2011","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.addr.2014.10.022_bb0915","author":"GlaxoSmithKline, Relenza\u00ae Rotadisk\u00ae"},{"key":"10.1016\/j.addr.2014.10.022_bb0920","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200005000-00005","article-title":"Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial","volume":"19","author":"Hedrick","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.10.022_bb0925","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jps.21501","article-title":"Cascade impactor practice for a high dose dry powder inhaler at 90L\/min: NGI versus modified 6-stage and 8-stage ACI","volume":"98","author":"Kamiya","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb0930","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jamp.2012.0975","article-title":"In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults","volume":"26","author":"Delvadia","year":"2013","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2014.10.022_bb0935","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0378-5173(01)00913-9","article-title":"Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM","volume":"232","author":"B\u00e9rard","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1750-2659.2012.00351.x","article-title":"Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics","volume":"7","author":"Sunagawa","year":"2013","journal-title":"Influenza Other Respi. Viruses"},{"key":"10.1016\/j.addr.2014.10.022_bb0945","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.322.7286.577","article-title":"Comparison of elderly people\u2019s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial","volume":"322","author":"Diggory","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2014.10.022_bb0950","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1086\/650176","article-title":"Fatal respiratory events caused by zanamivir nebulization","volume":"50","author":"Kiatboonsri","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.10.022_bb0955","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1086\/653450","article-title":"Fatal respiratory events caused by zanamivir nebulization","volume":"51","author":"Steel","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.10.022_bb0960","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/135965350300800301","article-title":"Safety and efficacy of nebulised zanamivir in hospitalized patients with serious influenza","volume":"8","author":"Ison","year":"2003","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.addr.2014.10.022_bb0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1750-2659.2012.00351.x","article-title":"Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics","volume":"7","author":"Sunagawa","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.addr.2014.10.022_bb0970","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza: a review","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0975","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10156-012-0481-9","article-title":"Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance","volume":"19","author":"Kashiwagi","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0980","author":"Hovione"},{"key":"10.1016\/j.addr.2014.10.022_bb0985","series-title":"The Formulation Development and Device Designing of Inavir\u00ae Dry Powder Inhaler","author":"Inoue","year":"2013"},{"key":"10.1016\/j.addr.2014.10.022_bb0990","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.00333-08","article-title":"CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity","volume":"53","author":"Yamashita","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.10.022_bb0995","first-page":"337","article-title":"In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses","volume":"63","author":"Kubo","year":"2010","journal-title":"Jpn. J. Antibiot."},{"key":"10.1016\/j.addr.2014.10.022_bb1000","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2009.07.002","article-title":"Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation","volume":"59","author":"Kawai","year":"2009","journal-title":"J. Infect."},{"key":"10.1016\/j.addr.2014.10.022_bb1005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/nature08260","article-title":"In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses","volume":"460","author":"Itoh","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.addr.2014.10.022_bb1010","author":"Biota"},{"key":"10.1016\/j.addr.2014.10.022_bb1015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/ers.10.15","article-title":"Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza","volume":"4","author":"Wong","year":"2010","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.addr.2014.10.022_bb1020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.10.022_bb1025","series-title":"Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients","author":"Moss","year":"2013"},{"key":"10.1016\/j.addr.2014.10.022_bb1030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.antiviral.2008.01.005","article-title":"Megaribavirin aerosol for the treatment of influenza A virus infections in mice","volume":"78","author":"Gilbert","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10753-009-9170-y","article-title":"Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice","volume":"33","author":"Shi","year":"2009","journal-title":"Inflammation"},{"key":"10.1016\/j.addr.2014.10.022_bb1040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.11.013","article-title":"Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model","volume":"93","author":"Verreault","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14728214.2011.607811","article-title":"Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations","volume":"16","author":"Pitman","year":"2011","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.addr.2014.10.022_bb1050","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1440-1843.2012.02150.x","article-title":"Pulmonary fungal infections","volume":"17","author":"Smith","year":"2012","journal-title":"Respirology"},{"key":"10.1016\/j.addr.2014.10.022_bb1055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408410903241444","article-title":"Epidemiology of invasive mycoses in North America","volume":"36","author":"Pfaller","year":"2010","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.addr.2014.10.022_bb1060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"Thoracic soc fungal working, an official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.022_bb1065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolised delivery of antifungal agents","volume":"4","author":"Le","year":"2010","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.addr.2014.10.022_bb1070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1183\/09031936.00163511","article-title":"Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis","volume":"40","author":"Hilberg","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.022_bb1075","first-page":"e001","article-title":"Use of aerosolised antifungals for the prophylaxis against and treatment of invasive pulmonary aspergillosis: climbing it because it is there?","volume":"S1","author":"Klepser","year":"2011","journal-title":"Pharm. Anal. Acta"},{"key":"10.1016\/j.addr.2014.10.022_bb1080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10717540490467375","article-title":"Development of liposomal amphotericin B dry powder inhaler formulation","volume":"11","author":"Shah","year":"2004","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb1085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jamp.2008.0715","article-title":"A review on the clinical use of inhaled amphotericin B","volume":"22","author":"Kuiper","year":"2009","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb1090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2012.07.012","article-title":"Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity","volume":"436","author":"Fauvel","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jps.22274","article-title":"Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulisation","volume":"100","author":"Gilani","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb1100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2012.04.004","article-title":"The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection","volume":"160","author":"Alsaadi","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb1105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2012.09.018","article-title":"Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis","volume":"83","author":"Rundfeldt","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1110","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.addr.2013.07.020","article-title":"Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases","volume":"65","author":"Andrade","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb1115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.addr.2011.03.011","article-title":"Production methods for nanodrug particles using the bottom-up approach","volume":"63","author":"Chan","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.10.022_bb1120","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1517\/17425240802457188","article-title":"Drug delivery strategies for improved azole antifungal action","volume":"5","author":"Yang","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb1125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.powtec.2012.01.045","article-title":"Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation","volume":"222","author":"Jafarinejad","year":"2012","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb1135","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.2147\/IJN.S34091","article-title":"New inhalation-optimised itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis","volume":"7","author":"Duret","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.10.022_bb1140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejpb.2013.03.005","article-title":"Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention","volume":"86","author":"Duret","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2012.03.010","article-title":"Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing","volume":"429","author":"Beinborn","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","article-title":"Characterization of nebulized liposomal amikacin (Arikace (TM)) as a function of droplet size","volume":"21","author":"Li","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.10.022_bb1155","series-title":"Respiratory Drug Delivery Orlando, FL","article-title":"Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance","author":"Cipolla","year":"2010"},{"key":"10.1016\/j.addr.2014.10.022_bb1160","series-title":"Respiratory Drug Delivery Europe 2013, Berlin, Germany","article-title":"Liposomal ciprofloxacin for inhalation retains integrity following nebulization","author":"Cipolla","year":"2013"},{"key":"10.1016\/j.addr.2014.10.022_bb1165","first-page":"1","article-title":"Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties","author":"Cipolla","year":"2014","journal-title":"AAPS Pharmscitech"},{"key":"10.1016\/j.addr.2014.10.022_bb1170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/157018007784620040","article-title":"In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains","volume":"4","author":"Gubernator","year":"2007","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.addr.2014.10.022_bb1175","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/jps.23203","article-title":"Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation","volume":"101","author":"Wallace","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb1180","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms12074414","article-title":"Isoniazid proliposome powders for inhalation\u2013preparation, characterization and cell culture studies","volume":"12","author":"Rojanarat","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb1185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pupt.2013.07.006","article-title":"Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach","volume":"27","author":"Patil-Gadhe","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.10.022_bb1190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/03639040903099769","article-title":"Controlled release antibiotics for dry powder lung delivery","volume":"36","author":"Adi","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1195","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s11095-010-0142-6","article-title":"Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile","volume":"27","author":"Cheow","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1200","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.colsurfa.2011.08.035","article-title":"The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics","volume":"389","author":"Cheow","year":"2011","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.addr.2014.10.022_bb1205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","article-title":"Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers","volume":"157","author":"Ungaro","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb1210","first-page":"88","article-title":"Isoniazid loaded chitosan microspheres for pulmonary delivery: preparation and characterization","volume":"2","author":"Kundawala","year":"2011","journal-title":"Der. Pharmacia Sinica"},{"key":"10.1016\/j.addr.2014.10.022_bb1215","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/02652048.2011.599437","article-title":"Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid","volume":"28","author":"Pourshahab","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2014.10.022_bb1220","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.2042-7158.2012.01531.x","article-title":"Preparation of sustained release rifampicin microparticles for inhalation","volume":"64","author":"Son","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2014.10.022_bb1225","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1208\/s12249-010-9428-6","article-title":"Rehydrated lyophilized rifampicin-loaded mPEG\u2013DSPE formulations for nebulization","volume":"11","author":"Abdulla","year":"2010","journal-title":"AAPS Pharmscitech"},{"key":"10.1016\/j.addr.2014.10.022_bb1230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2011.05.007","article-title":"Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery","volume":"414","author":"Doan","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1235","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ijpharm.2012.07.036","article-title":"Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting","volume":"436","author":"Diab","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2008.11.027","article-title":"One-step preparation of rifampicin\/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis","volume":"135","author":"Ohashi","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb1245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-008-9044-5","article-title":"Slow release formulations of inhaled rifampin","volume":"10","author":"Coowanitwong","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2014.10.022_bb1250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/08982100903103904","article-title":"3Development and optimization of solid lipid nanoparticles of amikacin by central composite design","volume":"20","author":"Varshosaz","year":"2010","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10837450.2010.529149","article-title":"Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design","volume":"17","author":"Varshosaz","year":"2012","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb1260","first-page":"35","article-title":"Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles","volume":"6","author":"Ghaffari","year":"2010","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.10.022_bb1265","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12247-010-9082-2","article-title":"Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols","volume":"5","author":"El-Gendy","year":"2010","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.addr.2014.10.022_bb1270","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2008.08.014","article-title":"Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery","volume":"365","author":"Pilcer","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1275","author":"Savara, Inc."},{"key":"10.1016\/j.addr.2014.10.022_bb1280","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/jps.23168","article-title":"Development of budesonide nanocluster dry powder aerosols: processing","volume":"101","author":"El-Gendy","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb1285","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.2014.27","article-title":"Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product","volume":"95","author":"Backman","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.10.022_bb1290","series-title":"Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients","author":"Moss","year":"2013"},{"key":"10.1016\/j.addr.2014.10.022_bb1295","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.antiviral.2008.01.005","article-title":"Megaribavirin aerosol for the treatment of influenza A virus infections in mice","volume":"78","author":"Gilbert","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1300","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10753-009-9170-y","article-title":"Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice","volume":"33","author":"Shi","year":"2009","journal-title":"Inflammation"},{"key":"10.1016\/j.addr.2014.10.022_bb1305","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.11.013","article-title":"Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model","volume":"93","author":"Verreault","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1310","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2012.07.012","article-title":"Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity","volume":"436","author":"Fauvel","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1315","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jps.22274","article-title":"Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulisation","volume":"100","author":"Gilani","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.10.022_bb1320","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2012.04.004","article-title":"The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection","volume":"160","author":"Alsaadi","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.10.022_bb1325","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1330","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2012.09.018","article-title":"Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis","volume":"83","author":"Rundfeldt","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.10.022_bb1335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.powtec.2012.01.045","article-title":"Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation","volume":"222","author":"Jafarinejad","year":"2012","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2014.10.022_bb1340","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.2147\/IJN.S34091","article-title":"New inhalation-optimised itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis","volume":"7","author":"Duret","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.10.022_bb1345","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s11095-012-0779-4","article-title":"New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis","volume":"29","author":"Duret","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.10.022_bb1350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2012.03.010","article-title":"Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing","volume":"429","author":"Beinborn","year":"2012","journal-title":"Int. J. Pharm."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14002300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14002300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T12:55:31Z","timestamp":1650459331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X14002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":270,"alternative-id":["S0169409X14002300"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2014.10.022","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2014.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}